The Joint Corp. (NASDAQ: JYNT) reported Q3 EPS of ($0.21), $0.22 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $30.19 million versus the consensus estimate of $28.38 million.

2024 Guidance
The company adjusted its guidance to account the potential impact of ongoing consumer headwinds.

System-wide sales are expected to be between $525 million and $535 million, adjusted from $530 million and $545 million and compared to $488.0 million in 2023.
System-wide comp sales for all clinics open 13 months or more are expected to be between 3% and 4% adjusted from in the mid-single digits in 2024 and compared to 4% in 2023.
New franchised clinic openings, excluding the impact of refranchised clinics, are expected to be between 55 and 60, adjusted from 60 and 75 and compared to 104 in 2023.

For earnings history and earnings-related data on The Joint Corp. (JYNT) click here.